Immunotherapy in Ovarian Cancer

PMID: 31079799
Journal: Surgical oncology clinics of North America (volume: 28, issue: 3, Surg. Oncol. Clin. N. Am. 2019 Jul;28(3):447-464)
Published: 2019-04-05

Wang W, Liu JR, Zou W


The phenotype and functionalities of the major immune cell subsets including myeloid cells, macrophages, dendritic cells, and T cells are altered in the ovarian cancer microenvironment. Immunosuppressive networks including inhibitory B7 family members and regulatory T cell-associated adenosine pathway have been defined in human ovarian cancer. In this review, the authors integrate emerging information on immunosuppressive mechanisms and T cell phenotype and discuss strategies of immunotherapeutic and vaccine regimens. Finally, crucial points regarding design of immuno-oncology clinical trials are reviewed.